Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance (Q46441674)

22 December 2017

title

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance (English)

1 reference

22 December 2017

author

James A. McCubrey

1

1 reference

22 December 2017

Massimo Libra

9

1 reference

22 December 2017

Ferdinando Nicoletti

1 reference

ORCID Public Data File 2021

author name string

S L Abrams

2

1 reference

22 December 2017

G Ligresti

3

1 reference

22 December 2017

N Misaghian

4

1 reference

22 December 2017

E W T Wong

5

1 reference

22 December 2017

L S Steelman

6

1 reference

22 December 2017

J Bäsecke

7

1 reference

22 December 2017

J Troppmair

8

1 reference

22 December 2017

F Nicoletti

10

1 reference

22 December 2017

S Molton

11

1 reference

22 December 2017

M McMahon

12

1 reference

22 December 2017

C Evangelisti

13

1 reference

22 December 2017

A M Martelli

14

1 reference

22 December 2017

publication date

7 August 2008

1 reference

22 December 2017

published in

Leukemia

1 reference

22 December 2017

volume

22

1 reference

22 December 2017

issue

11

1 reference

22 December 2017

page(s)

2080-2090

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.207

exact match

0 references

cites work

New agents for the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

ABC transporters in the balance: is there a role in multidrug resistance?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Signal transduction pathways that contribute to myeloid differentiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

The role of p73 in hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

BOK and NOXA are essential mediators of p53-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

The hunt for cancer-initiating cells: a history stemming from leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Clinical significance of TP53 mutation in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Genetics of therapy-related myelodysplasia and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.207

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.207

1 reference

22 December 2017

Dimensions Publication ID

0 references

1 reference

22 December 2017